WHO Issues Concern Over Acute Scarcity of Obesity Injections
Less than one in 10 individuals that would benefit from weight-loss injections including Wegovy have access to them, states the WHO as it releases its first advice on the medications.
With over a billion people worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.
Based on estimates, over two billion are projected to be obese by 2030 if no action is taken.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with comprehensive and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major barriers to universal availability to the injections that can help people shift substantial weight, explains the organization.
Skinny Jab Scarcity
Despite the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, per the health organization.
The advice encourages countries and companies to widen access, via approaches such as licensing agreements.
The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Drugs Work
The injections replicate a biological compound to reduce digestion speed, suppress the appetite and boost feelings of fullness so people consume fewer calories.
People commonly start to lose weight in the initial weeks of starting on the once-weekly jabs.
Studies suggests people may see weight return a year later of discontinuing the treatment, as their normal hunger come back.
To be overweight or obese elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight affects individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.